Zimmer Biomet (NYSE:ZBH) Rating Increased to Hold at BMO Capital Markets

Zimmer Biomet (NYSE:ZBH) was upgraded by investment analysts at BMO Capital Markets to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other research analysts have also recently weighed in on the stock. Truist Financial reissued a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. JPMorgan Chase & Co. reduced their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Monday. Finally, Wells Fargo & Company dropped their price target on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $102.33.

Zimmer Biomet Trading Up 1.9%

NYSE:ZBH opened at $89.24 on Wednesday. The company has a market capitalization of $17.26 billion, a PE ratio of 23.18, a price-to-earnings-growth ratio of 2.58 and a beta of 0.46. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $108.29. The stock has a fifty day simple moving average of $86.03 and a 200-day simple moving average of $89.75.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the prior year, the company earned $1.81 EPS. The firm’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts expect that Zimmer Biomet will post 8.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of the stock. DV Equities LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $25,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth $30,000. Gen Wealth Partners Inc purchased a new position in shares of Zimmer Biomet in the 4th quarter worth $31,000. Flagship Harbor Advisors LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter worth $32,000. Finally, Elevation Wealth Partners LLC boosted its holdings in Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.